Our Mission:
Accelerating the prevention and cure of myeloma and improving
the quality of life for patients and families
I am a...
About Multiple Myeloma
Multiple myeloma starts in the bone marrow plasma cells. It weakens the immune system and can affect many parts of the body by causing the bone marrow to create dysfunctional antibodies and plasma cells. Living with or treating this disease means making complicated decisions, and this requires searching for reliable, current information on multiple myeloma.
How Can the International Myeloma Foundation Help?
The International Myeloma Foundation (IMF) connects people to what matters most — research that pushes the field forward, education that clarifies complex topics, support tailored to individual needs, and advocacy that amplifies every voice. Patients, care partners, healthcare professionals, and researchers can access the knowledge, resources, and community they need from the IMF to navigate life with myeloma.
After a delayed multiple myeloma diagnosis, Oya Gilbert transformed his experience into a mission to improve health literacy through the power of hip hop. Learn how Oya became inspired to change lives, one lyric at a time. READ THE BLOG.
Join the International Myeloma Foundation for a FREE special webinar on June 25, 2026, at 5 pm PST | 6 pm MST | 7 pm CST | 8 pm EST. The webinar will cover the most important updates from the American Society of Clinical Oncology (ASCO), International Myeloma Working Group (IMWG), and European Hematology Association (EHA) annual meetings. REGISTER NOW.
The IMF is proud to announce that an oral presentation was conducted for the Black Swan Research Initiative’s® (BSRI) cure trial, Aggressive Smoldering Curative Approach Evaluating Novel Therapies and Transplant (ASCENT) at the European Hematology Association (EHA) 2026 Congress. This trial uses the quadruplet combination of daratumumab, carfilzomib, lenalidomide, and dexamethasone (Dara-KRd) in patients with high-risk smoldering multiple myeloma. READ THE PRESS RELEASE.
On June 13, results from the Phase 3 MonumenTAL-3 trial (Abstract #S100) were presented during the Plenary Abstracts Session at the 2026 European Hematology Association (EHA) Congress and simultaneously published in The New England Journal of Medicine.
Presented by Peter M. Voorhees, MD, of Atrium Health Levine Cancer Center and Wake Forest University School of Medicine, the study evaluated the efficacy and safety of talquetamab plus subcutaneous daratumumab, with or without pomalidomide (Tal-D and Tal-DP), versus daratumumab, pomalidomide, and dexamethasone (DPd) in patients with relapsed or refractory multiple myeloma who had received at least one prior therapy. LEARN MORE.
From August 18–24, 2026, intrepid cyclists — patients, care partners, and healthcare professionals — will cross Iceland’s breathtaking landscapes to raise vital funds for the International Myeloma Foundation’s mission.
